Robert Redner, MD
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Robert Redner, MD sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Robert Redner, MD: 2 sponsored US clinical trials, none currently recruiting.
Robert Redner, MD sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 1 trials.
Mid-pack sponsor footprint
Robert Redner, MD is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
NCT03839446
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
NCT01042704
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Therapeutic Areas
How the Robert Redner, MD early-phase archive is shaped
2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Robert Redner, MD: archived-pipeline peers nationwide
Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Robert Redner, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 archived trials
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Robert Redner, MD page
2 registered trials is a research-attention snapshot, not an endorsement of Robert Redner, MD or any single study.
- None of Robert Redner, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Acute Myeloid Leukemia is the condition Robert Redner, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Robert Redner, MD pipeline card: 2 registered trials from official public datasets.Report a data error.